{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:39:16Z","timestamp":1786973956768,"version":"build-2736575974"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>INTRODUCTION<\/jats:title><jats:p>Gantenerumab was investigated in Japanese participants with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD in two global phase 3 trials (GRADUATE I\/II), and a phase 2 trial in Japan (JP40959).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Of 1965 participants randomized in GRADUATE I\/II (global\u2010GRADUATE), 132 participants were enrolled from Japan (Japanese\u2010GRADUATE) and 67 Japanese participants were randomized 2:1:1 to high\u2010, low\u2010dose gantenerumab, and placebo in JP40959.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Slowing of cognitive and functional decline, and amyloid reduction in gantenerumab group compared to placebo group were greater in Japanese\u2010GRADUATE than in the global\u2010GRADUATE and JP40959. Plasma gantenerumab concentrations in the Japanese\u2010GRADUATE were slightly higher than in the global\u2010GRADUATE and comparable to JP40959. Gantenerumab was well tolerated in the Japanese\u2010GRADUATE and JP40959, matching the safety profile of the global\u2010GRADUATE.<\/jats:p><\/jats:sec><jats:sec><jats:title>DISCUSSION<\/jats:title><jats:p>Differences in results across the populations studied could be related to imbalances in baseline body weight, amyloid load, and disease severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>TRIAL REGISTRATION NUMBER<\/jats:title><jats:p>ClinicalTrials.gov ID: NCT03444870, NCT03443973; Japan Registry for Clinical Trials ID: jRCT2080224569.<\/jats:p><\/jats:sec><jats:sec><jats:title>Highlights<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Gantenerumab was evaluated in Japanese participants with Alzheimer's disease (AD) in two global phase 3 trials and a phase 2 trial in Japan.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Relative reduction in Clinical Dementia Rating Sum of Boxes (CDR\u2010SB) deterioration favored gantenerumab in Japanese\u2010GRADUATE (42%) more than in global\u2010GRADUATE (9%) and JP40959 (\u201324%).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Amyloid reduction in Japanese\u2010GRADUATE was greater than in global\u2010GRADUATE and JP40959.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Overall, 72.7% and 27.5% of Japanese\u2010 and global\u2010GRADUATE, respectively, achieved an amyloid\u2010negative status.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Cognitive and functional decline, and amyloid reduction could be related to baseline body weight and disease severity.<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1002\/alz.70192","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:03:34Z","timestamp":1745971414000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Japanese participant data from three gantenerumab trials in early Alzheimer's disease"],"prefix":"10.1002","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4621-9366","authenticated-orcid":false,"given":"Takashi","family":"Asada","sequence":"first","affiliation":[{"name":"Institute of Science Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Thanasopoulou","sequence":"additional","affiliation":[{"name":"Roche Product Development Neuroscience, F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Delmar","sequence":"additional","affiliation":[{"name":"Roche Product Development Neuroscience, F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Wojtowicz","sequence":"additional","affiliation":[{"name":"Roche Product Development Neuroscience, F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Smith","sequence":"additional","affiliation":[{"name":"Product Development Roche Products Ltd  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Yoshiyama","sequence":"additional","affiliation":[{"name":"Inage Neurology and Memory Clinic  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Department of Neurology National Center for Geriatrics and Gerontology  Obu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neurology National Hospital Organization Hiroshima\u2010Nishi Medical Center  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Isozaki","sequence":"additional","affiliation":[{"name":"Memory Clinical Toride  Toride Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoto","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Biometrics Department Chugai Pharmaceutical Co., Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Department Chugai Pharmaceutical Co., Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Tatsuda","sequence":"additional","affiliation":[{"name":"Specialty Clinical Development Department Chugai Pharmaceutical Co., Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tamaoka","sequence":"additional","affiliation":[{"name":"Department of Neurology Faculty of Medicine University of Tsukuba  Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024\u2010019\u20100333\u20105"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010210075"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009917"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S146788"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.38"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12328"},{"key":"e_1_2_9_8_1","first-page":"007","article-title":"Is beta\u2010amyloid accumulation a cause or consequence of Alzheimer's disease?","volume":"1","author":"Wang S","year":"2016","journal-title":"J Alzheimers Parkinsonism Dement"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa395"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010021\u201000813\u20108"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2909"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"},{"key":"e_1_2_9_18_1","first-page":"S42","article-title":"LB8: aducanumab titration dosing regimen: 36\u2010month analyses from PRIME, a phase 1b study in patients with early Alzheimer's disease","volume":"5","author":"Budd Haeberlein S","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_9_19_1","volume-title":"\u201cLEQEMBI\u00ae Intravenous Infusion\u201d (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan [press release]","author":"Eisai Co. Ltd, Biogen, Inc","year":"2023"},{"key":"e_1_2_9_20_1","volume-title":"FDA's Decision to Approve New Treatment for Alzheimer's Disease [News Release]","author":"US Food and Drug Administration (FDA)","year":"2021"},{"key":"e_1_2_9_21_1","volume-title":"FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval: Action Follows Confirmatory Trial to Verify Clinical Benefit [News Release]","author":"US Food and Drug Administration (FDA)","year":"2023"},{"key":"e_1_2_9_22_1","volume-title":"Biogen to Realign Resources for Alzheimer's Disease Franchise [News Release]","author":"Biogen","year":"2024"},{"key":"e_1_2_9_23_1","volume-title":"FDA Approves Treatment for Adults With Alzheimer's Disease [News Release]","author":"US Food and Drug Administration (FDA)","year":"2024"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2017.40"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u20102011\u2010110977"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.0c00364"},{"key":"e_1_2_9_27_1","unstructured":"ThanasopoulouA LaneC DelmarP et\u00a0al. GRADUATE I and II: Subgroup analyses from two phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer's disease (AD).Oral presentation at AAIC 2023; July 16\u201320 2023;Amsterdam Netherlands. Accessed July 17 2024.https:\/\/medically.roche.com\/global\/en\/neuroscience\/aaic\u20102023\/medical\u2010material\/AAIC\u20102023\u2010presentation\u2010thanasopoulou\u2010GRADUATE\u2010I\u2010and\u2010II\u2010subgroup\u2010analyses\u2010from\u2010two\u2010phase\u2010pdf.html"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022\u20103956(75)90026\u20106"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.11.2412\u2010a"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.06.1353"},{"key":"e_1_2_9_33_1","unstructured":"LandauS JagustW Alzheimer's Disease Neuroimaging Initiative (ADNI).Florbetapir processing methods. Rev June 25 2015. Accessed July 17 2024.https:\/\/adni.bitbucket.io\/reference\/docs\/UCBERKELEYAV45\/ADNI_AV45_Methods_JagustLab_06.25.15.pdf"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3475"},{"key":"e_1_2_9_35_1","volume-title":"Basic principles on Global Clinical Trials","author":"Ministry of Health, Labour and Welfare"},{"key":"e_1_2_9_36_1","unstructured":"BarkhofF KleinG ToniettoM et\u00a0al.GRADUATE I and II: Imaging findings from two phase III trials of subcutaneous gantenerumab in early Alzheimer's disease: with insights on amyloid PET tau PET and volumetric MRI.Oral presentation at AD\/PD\u2122 2023; March 28\u2010April 1 2023;Gothenberg Sweden. Accessed July 17 2024.https:\/\/medically.gene.com\/global\/en\/unrestricted\/neuroscience\/adpd\u20102023\/adpd\u20102023\u2010presentation\u2010barkhof\u2010graduate\u2010i\u2010and\u2010ii\u2010imagin.html"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101959"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11010032"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.06.1893"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13128"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024\u2010020\u20100358\u20109"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010017\u20100318\u2010y"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1412006"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:59:18Z","timestamp":1759957158000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/alz.70192"],"URL":"https:\/\/doi.org\/10.1002\/alz.70192","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70192"}}